EMPLOYMENT AGREEMENTEmployment Agreement • August 31st, 2020 • Immunovant, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledAugust 31st, 2020 Company Industry JurisdictionThis Employment Agreement (this “Agreement”) is entered into as of August 24, 2020, by and between Michael Elliott (the “Executive”) and IMVT Corporation (the “Company”).
IMMUNOVANT, INC. EMPLOYMENT AGREEMENTEmployment Agreement • December 20th, 2019 • Immunovant, Inc. • Blank checks • New York
Contract Type FiledDecember 20th, 2019 Company Industry JurisdictionThis Employment Agreement (this “Agreement”) is entered into as of April 15, 2019, by and between W. Bradford Middlekauff (the “Executive”) and Immunovant, Inc. (the “Company”).
EMPLOYMENT AGREEMENTEmployment Agreement • December 20th, 2019 • Immunovant, Inc. • Blank checks • New York
Contract Type FiledDecember 20th, 2019 Company Industry JurisdictionThis Employment Agreement (this “Agreement”) is entered into as of October 22, 2019, by and between Pamela Connealy (the “Executive”) and Immunovant, Inc. (the “Company”).
EMPLOYMENT AGREEMENTEmployment Agreement • December 20th, 2019 • Immunovant, Inc. • Blank checks • New York
Contract Type FiledDecember 20th, 2019 Company Industry JurisdictionThis Employment Agreement (this “Agreement”) is entered into as of July 8, 2019, by and between Robert Zeldin (the “Executive”) and Immunovant, Inc. (the “Company”).
EMPLOYMENT AGREEMENTEmployment Agreement • December 20th, 2019 • Immunovant, Inc. • Blank checks • New York
Contract Type FiledDecember 20th, 2019 Company Industry JurisdictionThis Employment Agreement (this “Agreement”) is entered into as of May 30, 2019, by and between Pete Salzmann (the “Executive”) and Immunovant, Inc. (the “Company”).
EMPLOYMENT AGREEMENTEmployment Agreement • December 20th, 2019 • Immunovant, Inc. • Blank checks • New York
Contract Type FiledDecember 20th, 2019 Company Industry JurisdictionThis Employment Agreement (this “Agreement”) is entered into as of October 9, 2019, by and between Julia G. Butchko (the “Executive”) and Immunovant, Inc. (the “Company”).